Perflutren Lipid Microsphere Intravenous Suspension
Glioblastoma Multiforme of Brain
Sunnybrook Health Sciences CentrePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the Glioblastoma Multiforme of Brain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tvi-Brain-1 TVAX Biomedical | Phase 2/3 | B |
Belinostat Emory University | Phase 2 | CCC |
Ruxolitinib Baptist Health South Florida | Phase 2 | CCC |
Avelumab Clinique Neuro-Outaouais | Phase 2 | CCC |
Pembrolizumab University Hospital, Geneva | Phase 1/2 | CCC |
View all 26 →
Same molecule, other indications
Perflutren Lipid Microsphere Intravenous Suspension is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →